title: The latest in antiretroviral therapy.
abstract: The XVI International AIDS Conference (AIDS 2006), organized by the International AIDS Society (IAS), took place August 12-18 in Toronto, Canada. It was attended by over 26,000 participants from more than 170 countries and featured more than 4,500 abstracts as well as an array of community and cultural activities. The theme of the meeting was "Time to deliver", emphasizing the continued need and urgency in bringing effective HIV prevention and treatment strategies to those living with and affected by HIV/AIDS. The meeting's agenda was broad and included policy and programmatic topics as well as scientific research. This report focuses on reports presented at the conference that directly deal with antiretroviral therapy. This is primarily because of the nature of the venue where it is intended to be published (Drug News & Perspectives) as well as the expertise of the author. It is not a lack of recognition of the other equally important topics and discussions that took place at AIDS 2006. The author is solely responsible for the selection of topics and presentations to be included in this report.
authors.affiliation: Mayo Clinic, Division of Infectious Diseases, 200 First Street SW, Rochester, MN 55905, USA. temesgen.zelalem@mayo.edu
authors.forename: Zelalem
authors.initials: Z
authors.lastname: Temesgen
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D044966:Anti-Retroviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000627:therapeutic use; D000069454:Darunavir; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D000077592:Maraviroc; D009570:Nitriles; D009930:Organic Chemicals / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011724:Pyridazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors; D013449:Sulfonamides / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D044966:Anti-Retroviral Agents; D000911:Antibodies, Monoclonal; D003510:Cyclohexanes; D015507:Drugs, Investigational; D009570:Nitriles; D009930:Organic Chemicals; D010879:Piperazines; D011724:Pyridazines; D011743:Pyrimidines; D011760:Pyrrolidinones; D019707:Receptors, Chemokine; D013449:Sulfonamides; D014230:Triazoles; C451734:etravirine; D000068898:Raltegravir Potassium; C481504:ibalizumab; D000077592:Maraviroc; C486781:vicriviroc; D000069454:Darunavir